ArticleCarcinogenesis2015
Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids.
Article in Carcinogenesis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 55 citations in OpenAlex.
- Comprehensive big data analysis reveals SLC10A3 as a potential biomarker in head and neck cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- The Impact of Cholecystectomy on Colorectal Cancer Risk: A Comprehensive Review on Risk Factors and the Association.Current gastroenterology reports · 2025Review
- Targeting Bile-Acid Metabolism: Nutritional and Microbial Approaches to Alleviate Ulcerative Colitis.Nutrients · 2025Review
- A Retrospective Cohort Propensity-Matched Analysis of Colorectal Cancer Risk in Isolated Small Intestinal Crohn's Disease.Gastro hep advances · 2025Review
- Development of an immune-related gene prognostic risk model and identification of an immune infiltration signature in the tumor microenvironment of colon cancer.BMC gastroenterology · 2023Article
- SVM-DO: identification of tumor-discriminating mRNA signatures via support vector machines supported by Disease Ontology.Turkish journal of biology = Turk biyoloji dergisi · 2023Article
- Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatment.Oncogene · 2022Review
- Omega-3 Polyunsaturated Fatty Acids, Gut Microbiota, Microbial Metabolites, and Risk of Colorectal Adenomas.Cancers · 2022Article
- Gastrointestinal neoplasia: carcinogenic interaction between bile acids and Helicobacter pylori in the stomach.The Journal of clinical investigation · 2022Article
- Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs.Biochemical pharmacology · 2022Review
- Transcription Factor FXR Activates DHRS9 to Inhibit the Cell Oxidative Phosphorylation and Suppress Colon Cancer Progression.Analytical cellular pathology (Amsterdam) · 2022Article
- Differential Actions of Muscarinic Receptor Subtypes in Gastric, Pancreatic, and Colon Cancer.International journal of molecular sciences · 2021Review
- Exploiting unique features of the gut-brain interface to combat gastrointestinal cancer.The Journal of clinical investigation · 2021Review
- Metformin, Microbiome and Protection Against Colorectal Cancer.Digestive diseases and sciences · 2021Review
- A guide to plasma membrane solute carrier proteins.The FEBS journal · 2021Review
- Overcoming Obstacles to Targeting Muscarinic Receptor Signaling in Colorectal Cancer.International journal of molecular sciences · 2021Review
- Identification prognosis-associated immune genes in colon adenocarcinoma.Bioscience reports · 2020Article
- Farnesoid X receptor antagonizes Wnt/β-catenin signaling in colorectal tumorigenesis.Cell death & disease · 2020Article
- Prognostic Model of Colorectal Cancer Constructed by Eight Immune-Related Genes.Frontiers in molecular biosciences · 2020Article
- Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer.The Journal of biological chemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Although epidemiological evidence in humans and bile acid feeding studies in rodents implicate bile acids as tumor promoters, the role of endogenous bile acids in colon carcinogenesis remains unclear. In this study, we exploited mice deficient in the ileal apical sodium-dependent bile acid transporter (ASBT, encoded by SLC10A2) in whom fecal bile acid excretion is augmented more than 10-fold. Wild-type and Asbt-deficient (Slc10a2 (-/-) ) male mice were treated with azoxymethane (AOM) alone to examine the development of aberrant crypt foci, the earliest histological marker of colon neoplasia and a combination of AOM and dextran sulfate sodium to induce colon tumor formation. Asbt-deficient mice exhibited a 54% increase in aberrant crypt foci, and 70 and 59% increases in colon tumor number and size, respectively. Compared to littermate controls, Asbt-deficient mice had a striking, 2-fold increase in the number of colon adenocarcinomas. Consistent with previous studies demonstrating a role for muscarinic and epidermal growth factor receptor signaling in bile acid-induced colon neoplasia, increasing bile acid malabsorption was associated with M3 muscarinic and epidermal growth factor receptor expression, and activation of extracellular signal-related kinase, a key post-receptor signaling molecule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.